2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Secondary Hyperparathyroidism: new trials by email Literature Review of Secondary Hyperparathyroidism trials Research Report on Secondary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism Etelcalcetide - Secondary Hyperparathyroidism | Phase 2 | Terminated | KAI Pharmaceuticals | 30 | 2012-03-01 | 2017-04-13 |
| Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients Cinacalcet HCl - Secondary Hyperparathyroidism, Hypercalcemia | Phase 1 / Phase 2 | Terminated | Montefiore Medical Center | 4 | 2007-02-09 | 2025-04-29 |
Hyperparathyroidism, Secondary (2) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Hypercalcemia (1)
Calcium Metabolism Disorders (2) · Endocrine System Diseases (2) · Hyperparathyroidism (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Parathyroid Diseases (2) · Avitaminosis (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Chronic Disease (1) · Deficiency Diseases (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1)
Cinacalcet (1) · etelcalcetide hydrochloride (1)
KAI Pharmaceuticals (1) · Montefiore Medical Center (1)
United States (1)
M D (1) · Maria Coco, MD, MS (1)